alanine aminotransferase/brjóstakrabbamein

Krækjan er vistuð á klemmuspjaldið

Veldu tegund tegund

7 niðurstöður

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

1. Test population: Patients with stage III gastric cancer confirmed by postoperative pathology 2. Sample size calculation: single arm design was used in this study, and the main outcome was progression free survival. In this study, PD-L1 + CPS ≥ 10% / MSI-H + / EB +, the sample size was estimated

Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Inclusion criteria: 1. Patients with stage IV breast cancer with metastases demonstrated by appropriate imaging techniques 2. Histologically or cytologically confirmed tumor 3. Age of 18 years or more 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 5. Patients have failed,

Ribociclib and Bicalutamide in AR+ TNBC

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OUTLINE: This is a multi-center study. INVESTIGATIONAL TREATMENT: - bicalutamide - 150mg po daily D1 - D28 (Cycle = 28 days) - ribociclib po daily D1 - D21 of 28 day cycle PHASE I SAFETY RUN-IN COHORT: The maximum tolerated dose (MTD) of bicalutamide in combination with ribociclib will be determined

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

1. Introduction to investigational treatment(s) and other study treatment(s) 1.1 Overview of gemcitabine Gemcitabine (29,29-difluoro 29-deoxycytidine, dFdC) which developed from cytosine arabinoside (Ara-C) is an nucleoside analog used as chemotherapy. It was intended as an antiviral drug in

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OUTLINE: This is a multi-center trial. INVESTIGATIONAL TREATMENT: - Palbociclib 125 mg will be administered orally once daily on days 1-21 (D1-D21) of each 28-day cycle. Subjects will not take palbociclib on D22-D28. - Tamoxifen 20 mg will be administered orally once daily for every day of the

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OUTLINE: This is a multi-center trial. SEQUENCING: DNA from archived tumor samples collected at the time of surgery (residual disease post neoadjuvant chemotherapy) will be extracted and sequenced. The resulting sequencing data will be interrogated for known genomic drivers of sensitivity or

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OUTLINE: This is a multi-center study. Safety Run-in will be for the first 12 patients on study only (6 in cohort 1 and 6 in cohort 2). Patients in the safety run will be included in the efficacy analysis on intent to treat basis: Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib 16-30 mg

Skráðu þig á
facebook síðu okkar

Herbal & Natural Medicine

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

Virkar á 55 tungumálum
Jurtalækningar studdir af vísindum
Jurtaviðurkenning eftir ímynd
Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
Lestu vísindarit sem tengjast leit þinni
Leitaðu að lækningajurtum eftir áhrifum þeirra
Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum